Vivesto AB (STO:VIVE)

Market Cap	136.84M +10.3%
Revenue (ttm)	n/a
Net Income	-34.08M
EPS	-6.33
Shares Out	11.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	216,603
Open	14.04
Previous Close	14.40
Day's Range	11.44 - 14.04
52-Week Range	7.00 - 31.90
Beta	0.83
Analysts	n/a
Price Target	n/a
Earnings Date	May 26, 2026

About Vivesto AB

Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Employees: 4
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: VIVE